---
title: "Lysergide (DT120) in Generalized anxiety disorder: Effects of other drugs"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Effects of other drugs. Topics: Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor), Other CYP2D6 inhibitors, MDMA co-administration, Ketanserin given after LSD, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Lysergide

<a id="topic-2.1.2.9.1-1"></a>

### Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor)

> “The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants.”
> “Paroxetine did not alter pleasant subjective effects of LSD”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

> “The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism.”
> “The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers.”
> “The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6.”
> “For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.9.1-2"></a>

### Other CYP2D6 inhibitors

> “A similar or substantial increase in plasma LSD concentrations could be expected when patients who are on antidepressants that inhibit CYP2D6 (e.g., fluoxetine, paroxetine, duloxetine, and bupropion) and are treated with LSD-assisted therapy.”
> “This interaction warrants further study.”

Source: [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)

> “Consideration should also be given to discontinuing CYP2D6 inhibitors and allowing sufficient time for the enzyme to regenerate (up to 2 weeks) before LSD is used.”
> “Alternatively, in the presence of CYP2D6 inhibitors, the dose of LSD should be reduced, based on the present findings.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

<a id="topic-2.1.2.9.1-3"></a>

### MDMA co-administration

> “MDMA slightly altered the pharmacokinetics of LSD.”
> “The plasma LSD elimination half-life was longer in the LSD + MDMA condition (5.2 h) compared with LSD alone (3.9 h; T = 5.00; p < 0.001).”
> “Thus, MDMA and LSD primarily interact pharmacokinetically and not pharmacodynamically.”
> “MDMA is a strong inhibitor of CYP2D6, turning any CYP2D6 extensive or rapid metabolizer into a poor metabolizer within approximately 2 h”

Source: [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)

<a id="topic-2.1.2.9.1-4"></a>

### Ketanserin given after LSD

> “Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 hours with placebo to 3.5 hours.”
> “Ketanserin did not alter the pharmacokinetics of LSD.”
> “Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy.”

Source: [Becker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9926053/)

<a id="topic-2.1.2.9.1-5"></a>

### Ketanserin, olanzapine, and lorazepam as rescue medications: registered study

> “The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone”

Source: [ClinicalTrials.gov NCT05964647](https://clinicaltrials.gov/study/NCT05964647)

<a id="topic-2.1.2.9.1-6"></a>

### Enzyme induction and inhibition in vitro

> “Enzyme induction with rifampicin distinctly increased the formation of both metabolites, whereas treatment with omeprazole only slightly increased formation of nor-LSD.”
> “Genetic polymorphisms and drug interactions could therefore influence pharmacokinetics and pharmacodynamics of LSD.”
> “Drug-drug interaction studies in humans are required to further assess the clinical relevance of these findings.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

<a id="topic-2.1.2.9.1-7"></a>

### Antidepressants and lithium: regulatory guidance on pharmacodynamic interactions

> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for 3 weeks or more may reduce the subjective effects of psychedelic drugs.”
> “Use of tricyclic antidepressants or lithium for 3 weeks or more may potentiate the subjective effects of psychedelic drugs, creating a potential psychiatric safety concern.”
> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for less than 3 weeks may also potentiate the subjective effects of psychedelic drugs.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
